Drug Search Results
More Filters [+]

Otilonium bromide

Alternative Names: otilonium bromide, octylonium bromide, octylonium, Doralin
Latest Update: 2023-09-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Calcium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Bangladesh | Belgium | Bulgaria | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Greece | Hong Kong | Hungary | India | Indonesia | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Saudi Arabia | Spain | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Menarini
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Otilonium bromide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Irritable Bowel Syndrome|Spasm|Abdominal Pain

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

The DOMINO trial: Diet Or Medication in Irritable bowel syNdrOme

P4

Completed

Spasm|Irritable Bowel Syndrome|Abdominal Pain

2019-11-14

Randomized Prospective Trial

P4

Completed

Spasm

2013-05-01

DW-TRP001

P4

Unknown status

Irritable Bowel Syndrome

2013-02-01

2005-001655-38

P4

Completed

Irritable Bowel Syndrome

2007-03-06

Recent News Events